SOLICITATION NOTICE
Q -- GENERATION OF LLAMA MONOCLONAL ANTIBODIES AGAINST THE E. COLLI BAMA PROTEIN
- Notice Date
- 8/17/2015
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, Nat'l Institute of Diabetes, Digestive, & Kidney Diseases, 2 Democracy Plaza, Suite 700W, 6707 Democracy Blvd., MSC 5455, Bethesda, Maryland, 20892-5455
- ZIP Code
- 20892-5455
- Solicitation Number
- NIHLM2015582
- Archive Date
- 8/22/2015
- Point of Contact
- V. Lynn Griffin, Fax: 301-480-8501, MAXWELL KIMPSON,
- E-Mail Address
-
griffinv@mail.nih.gov, Max.Kimpson@nih.gov
(griffinv@mail.nih.gov, Max.Kimpson@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NIHLM2015552 and is issued as a Request for Quotation (RFQ). The solicitation /contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2005-82. The North American Industry Classification (NAICS) Code is 334516 with a size standard of 500. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. The National Institutes of Health (NIH), National Institute of Digestive, Diabetes & Kidney Diseases (NIDDK) has a requirement to procure GENERATION OF LLAMA MONOCLONAL ANTIBODIES AGAINST THE E. COLLI BAMA PROTEIN. Unlike most mammalian antibodies, camelid monoclonal antibodies, called vHHs or nanobodies, generated in llama, camel or alpaca consist of a single heavy chain. In recent years, nanobodies have been increasingly used in structural studies and in biotechnological and pharmaceutical applications. Nanobodies are small in size and can access novel and difficult-to-reach protein epitopes that cannot be accessed by traditional antibodies. Access to smaller epitopes often leads to receptor/active-site neutralization and enzyme inhibition. A lot of research published to date demonstrates remarkable results using nanobodies against flexible multi-domain proteins, large protein complexes and membrane proteins. While the results and applications have been exceptional, the generation of nanobodies is still rather expensive. Unlike conventional antibodies, the very nature of nanobodies makes them ideal for expression in bacteria. In our case, we intend to generate a nanobody against an essential component of a multi-protein outer membrane complex in E. coli called the Bam (barrel assembly machinery) complex. This complex is essential for the biogenesis of outer membrane proteins and hence is critical for cell viability. As an essential factor the Bam complex is a potential target for the development of novel antibiotics. To date, no simple and reliable method of inactivating the Bam complex and studying the subsequent effects on cellular processes has been developed. We would like to generate a nanobody that binds effectively to a key component of the Bam complex called BamA in vivo and inactivates it. For this purpose, we need the services of a commercial vendor who specializes in llama nanobody production. We will supply the purified antigen (BamA) to the vendor who will use it to immunize a llama, generate the nanobodies, and perform screening and sequencing of the best nanobodies. At the end of the contract period, they will deliver the gene sequences of the best nanobodies against BamA to us. The gene encoding the nanobody will be cloned into an appropriate plasmid and expressed with an N-terminal signal sequence in E. coli in our laboratory. Services Required from Outside Vendors: Initially, a llama will be immunized with purified BamA provided by our laboratory. Once the llama generates a stable repertoire of antibodies against BamA, lymphocytes will be collected, the mRNAs for the nanobodies will be extracted and a phage-display vector based cDNA library will be generated by synthesizing cDNA from mRNA followed by PCR amplification and cloning into a standard phage display vector. The generated library of phages will display a different nanobody for each phage. The best binding nanobody clones will be screened from the phage-display library by multiple rounds of panning using an ELISA based screening technique. Only the phages displaying specific nanobodies that bind to BamA with high efficiency will be isolated and the nanobody DNA sequenced from the corresponding vector. The entire process from llama immunization to sequencing of the best nanobody clones will be performed by the vendor over a time frame of approximately 6 months. The vendor shall deliver the sequenced nanobody DNA to us in a plasmid and we will perform the subsequent steps of subcloning and expression in our laboratory. The requirement listed is requested to submit a capability statement to assist the Government in determining in accordance with Federal Acquisition Regulation (FAR) 19.502-2(b) whether or not this procurement will be set-aside for any of the programs described above. The intended procurement will be classified under North American Industrial Classification (NAICS) code 541990 with a size standard 15 Million. All respondents are requested to identify their firm's size and type of business. Interested firms responding to this market survey must provide (a) capability statement demonstrating their experience, skills and capability to fulfill the Government's requirements for the above. The capability statement shall be in sufficient enough detail, but not to exceed 15 pages, so that the Government can determine the experience and capability of your firm to provide the requirements above. Your capability statement, not to exceed 15 pages, should include references. Responses: E-MAIL will be accepted and can be sent to griffinv@mail.nih.gov The offeror must include a completed copy of the following provisions: 1) FAR Clause 52.212-1 Instructions to Offerors - Commercial items; 2) FAR Clause 52.212-2, Evaluation - Commercial Items. As stated in FAR Clause 52.212-2 (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be advantageous to the Government, price and other factors considered. The following factors will be used equally to evaluate offers: Technical Evaluation, Price, and Past Performance. Note: Past Performance Information: Vendors must submit a listing of the most recent contracts/awards (minimum of 3) which demonstrate similar work in nature to this Solicitation. Contracts/awards may include those entered with the Federal Government, state and local governments and commercial concerns. Include the following information for each contract or subcontract: 1.Name of Contracting Organization 2.Contract Number (for subcontracts provide the prime contract number and the subcontract number) 3.Contract Type 4.Total Contract Value 5.Description of Requirement 6.Contracting Officer's Name and Telephone Number 7.Program Manager's Name and Telephone Number 3) FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items; 4) FAR Clause 52.212-4, Contract Terms and Conditions - Commercial Items; 5) FAR Clause 52-212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items - Deviation for Simplified Acquisitions. The Dun and Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN) and the certification of business size shall be included. The clauses are available in full text at https://www.acquisition.gov PLEASE NOTE: In order to receive an award, contractor must be registered and have valid certification in the System For Award Management (SAM) http://www.sam.gov Interested vendors capable of providing the Government with the items specified in this synopsis should submit their quotation to the below address. Quotations will be due on or before August 21, 2015 at 11:00 a.m. EST. Offersors shall provide an original and one copy of your quotation. The quotation must reference Solicitation number NIHLM2015582. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency. Quotations may be submitted electronically to Verne Griffin at griffinv@mail.nih.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDDKD/NIHLM2015582/listing.html)
- Record
- SN03841341-W 20150819/150817234726-f36f672508d040c28fe873dd2ec76423 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |